Cargando…

Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrell, Nicholas W., Archer, Stephen L., DeFelice, Albert, Evans, Steven, Fiszman, Monica, Martin, Thomas, Saulnier, Muriel, Rabinovitch, Marlene, Schermuly, Ralph, Stewart, Duncan, Truebel, Hubert, Walker, Gennyne, Stenmark, Kurt R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641734/
https://www.ncbi.nlm.nih.gov/pubmed/23662201
http://dx.doi.org/10.4103/2045-8932.109940
_version_ 1782268052370358272
author Morrell, Nicholas W.
Archer, Stephen L.
DeFelice, Albert
Evans, Steven
Fiszman, Monica
Martin, Thomas
Saulnier, Muriel
Rabinovitch, Marlene
Schermuly, Ralph
Stewart, Duncan
Truebel, Hubert
Walker, Gennyne
Stenmark, Kurt R.
author_facet Morrell, Nicholas W.
Archer, Stephen L.
DeFelice, Albert
Evans, Steven
Fiszman, Monica
Martin, Thomas
Saulnier, Muriel
Rabinovitch, Marlene
Schermuly, Ralph
Stewart, Duncan
Truebel, Hubert
Walker, Gennyne
Stenmark, Kurt R.
author_sort Morrell, Nicholas W.
collection PubMed
description Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have been significant advances in our understanding of the genetic, cell and molecular basis of PAH over the last few years. This research has identified important new targets that could be explored as potential therapies for PAH. In this review we discuss whether further exploitation of vasoactive agents could bring additional benefits over existing approaches. Approaches to enhance smooth muscle cell apotosis and the potential of receptor tyrosine kinase inhibition are summarised. We evaluate the role of inflammation, epigenetic changes and altered glycolytic metabolism as potential targets for therapy, and whether inherited genetic mutations in PAH have revealed druggable targets. The potential of cell based therapies and gene therapy are also discussed. Potential candidate pathways that could be explored in the context of experimental medicine are identified.
format Online
Article
Text
id pubmed-3641734
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-36417342013-05-09 Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension Morrell, Nicholas W. Archer, Stephen L. DeFelice, Albert Evans, Steven Fiszman, Monica Martin, Thomas Saulnier, Muriel Rabinovitch, Marlene Schermuly, Ralph Stewart, Duncan Truebel, Hubert Walker, Gennyne Stenmark, Kurt R. Pulm Circ Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have been significant advances in our understanding of the genetic, cell and molecular basis of PAH over the last few years. This research has identified important new targets that could be explored as potential therapies for PAH. In this review we discuss whether further exploitation of vasoactive agents could bring additional benefits over existing approaches. Approaches to enhance smooth muscle cell apotosis and the potential of receptor tyrosine kinase inhibition are summarised. We evaluate the role of inflammation, epigenetic changes and altered glycolytic metabolism as potential targets for therapy, and whether inherited genetic mutations in PAH have revealed druggable targets. The potential of cell based therapies and gene therapy are also discussed. Potential candidate pathways that could be explored in the context of experimental medicine are identified. Medknow Publications 2013 /pmc/articles/PMC3641734/ /pubmed/23662201 http://dx.doi.org/10.4103/2045-8932.109940 Text en Copyright: © Pulmonary Circulation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets
Morrell, Nicholas W.
Archer, Stephen L.
DeFelice, Albert
Evans, Steven
Fiszman, Monica
Martin, Thomas
Saulnier, Muriel
Rabinovitch, Marlene
Schermuly, Ralph
Stewart, Duncan
Truebel, Hubert
Walker, Gennyne
Stenmark, Kurt R.
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
title Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
title_full Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
title_fullStr Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
title_full_unstemmed Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
title_short Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
title_sort anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
topic Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641734/
https://www.ncbi.nlm.nih.gov/pubmed/23662201
http://dx.doi.org/10.4103/2045-8932.109940
work_keys_str_mv AT morrellnicholasw anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT archerstephenl anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT defelicealbert anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT evanssteven anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT fiszmanmonica anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT martinthomas anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT saulniermuriel anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT rabinovitchmarlene anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT schermulyralph anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT stewartduncan anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT truebelhubert anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT walkergennyne anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension
AT stenmarkkurtr anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension